Literature DB >> 29561442

Comparison of patients with avian influenza A (H7N9) and influenza A (H1N1) complicated by acute respiratory distress syndrome.

Hongyan Li1, Heng Weng1, Changqing Lan2, Hongying Zhang1, Xinhang Wang1, Jianguang Pan1, Lulu Chen1, Jinbao Huang1.   

Abstract

The aim of this study was to compare the clinical features of patients with avian influenza A (H7N9) and influenza A (H1N1) complicated by acute respiratory distress syndrome (ARDS).The clinical data of 18 cases of H7N9 and 26 cases of H1N1 with ARDS were collected and compared in the respiratory intensive care unit (RICU) of Fuzhou Pulmonary Hospital of Fujian from March 2014 to December 2016.Patients with H7N9 had a higher acute physiology and chronic health evaluation-II score (P < .05) and lung injury score (P < .05). The rates of coexisting diabetes mellitus, hyperpyrexia, and bloody sputum production were significantly higher in the H7N9 group than in the H1N1 group (P < .05). The H7N9 group had a longer duration of viral shedding from the onset of illness (P < .05) and from the initiation of antiviral therapy (P < .05) to a negative viral test result than the H1N1 group. Patients with H7N9 had higher rates of invasive mechanical ventilation; serious complications, including alimentary tract hemorrhage, pneumothorax or septum emphysema, hospital-acquired pneumonia (HAP) and multiple organ dysfunction syndrome (MODS); and hospital mortality (P < .05). At the 6th month of follow-up, the rates of bronchiectasia, reticular opacities, fibrous stripes, and patchy opacities on chest computed tomography (CT) were significantly higher in the H7N9 group than in the H1N1 group (P < .05). Based on multiple logistic regression analysis, H7N9 influenza viral infection was associated with a higher risk of the presence of severe ARDS than H1N1 influenza viral infection (odds ratio 8.29, 95% confidence interval [CI] 1.53-44.94; P < .05).Compared to patients with H1N1, patients with H7N9 complicated by ARDS had much more severe disease. During long-term follow-up, more changes in pulmonary fibrosis were observed in patients with H7N9 than in patients with H1N1 during the convalescent stage.

Entities:  

Mesh:

Year:  2018        PMID: 29561442      PMCID: PMC5895352          DOI: 10.1097/MD.0000000000010194

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Humans infected with either avian influenza A (H7N9)[ or influenza A (H1N1)[ can exhibit severe respiratory disease. Acute respiratory distress syndrome (ARDS) has a high incidence in severe cases and is the main cause of avian influenza-related death.[ To date, data regarding comparisons between patients with H7N9 and those with H1N1 have been reported,[ but specific studies comparing the 2 diseases in terms of ARDS are rare. Herein, the clinical features and prognoses of patients with H7N9 avian influenza and those with H1N1 influenza were retrospectively and comparatively analyzed to further improve the understanding of ARDS caused by influenza viruses.

Methods

Patients

This study was established in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Fuzhou Pulmonary Hospital of Fujian, Educational Hospital of Fujian Medical University. The Ethics Committee waived the requirement for informed consent for this study, but all patient data were analyzed anonymously. The clinical data, including epidemiology, clinical manifestations, imaging examinations, and laboratory examinations, were collected from 18 patients with avian influenza A (H7N9) and 26 patients with influenza A (H1N1) complicated by ARDS in the respiratory intensive care unit (RICU) of the Fuzhou Pulmonary Hospital of Fujian from March 2014 to December 2016. All patients with H7N9 or H1N1 were diagnosed according to the diagnosis and treatment programmes for influenza issued by the Chinese Ministry of Health (National Health and Family Planning Commission).[ The respiratory specimens (nasopharyngeal swab, sputum, extracted tracheal aspirate, or bronchoalveolar lavage fluid) in all clinically suspected cases of influenza viral infection were positive for avian influenza A (H7N9) virus or influenza A (H1N1) virus by reverse transcription polymerase chain reaction (RT-PCR), which was performed as a qualitative assay. After admission, serial sampling of all respiratory secretions mentioned above (nasopharyngeal swab or lower respiration sample) was performed daily for viral monitoring until the clinical specimens were consistently negative twice during a time interval of 24 hours. Patients with ARDS were diagnosed according to the diagnostic criteria of the Berlin definition[ as follows: the timing was within 1 week of a known clinical insult or new/worsening respiratory symptoms; chest imaging (chest x-ray or computed tomography [CT] scan) showed bilateral opacities that were not fully explained by effusions, lobar/lung collapse, or nodules; hypoxemia (positive end expiratory pressure [PEEP] or continuous positive airway pressure [CPAP] ≥5 cm H2O) was classified as mild (the ratio of arterial partial pressure of oxygen to inspiratory oxygen fraction [PaO2/FiO2] 201–300 mmHg), moderate (PaO2/FiO2 101–200 mmHg), or severe (PaO2/FiO2 ≤100 mm Hg); and the origin of edema was assessed as respiratory failure that was not fully explained by cardiac failure or fluid overload, and an objective assessment (e.g., echocardiography) was necessary to exclude hydrostatic edema if no risk factor was present.

Statistical analysis

Data were described as the median (interquartile range, IQR) or number (%). The comparisons of the features between the different subtypes of influenza (H7N9 and H1N1) were performed with the Wilcoxon signed-rank test to compare the medians of continuous variables and Fisher exact test or the chi-squared test to compare proportions. The association between the different subtypes of influenza viral infection (H7N9 and H1N1) and the risk of severe ARDS presentation and death was assessed using multivariable logistic regression analysis, adjusted for age, sex, and coexisting diabetes. All analyses were performed with SPSS 19.0 statistical analysis software (IBM, Armonk, NY). A P-value <.05 was considered statistically significant.

Results

Epidemiological characteristics

The epidemiological characteristics of the 2 groups are shown in Table 1. The number of patients aged ≥65 years, the acute physiology and chronic health evaluation-II (APACHE-II) score and the lung injury score were higher in the H7N9 group than in the H1N1 group (P < .05) on admission. The rate of diabetes mellitus was statistically higher in the H7N9 group than in H1N1 group (P < .05).
Table 1

Epidemiological features in the H7N9 and H1N1 groups.

Epidemiological features in the H7N9 and H1N1 groups.

Clinical manifestations, laboratory results, and imaging findings

The clinical characteristics of the patients in the 2 groups are shown in Table 2. The 2 groups were mainly characterized by fever, shortness of breath, cough, hemoptysis, poor appetite, and fatigue, and hyperpyrexia (>39.0 °C) and bloody sputum were more common in the H7N9 group than in the H1N1 group (P < .05).
Table 2

Clinical symptoms, laboratory results, and imaging features of the H7N9 and H1N1 groups.

Clinical symptoms, laboratory results, and imaging features of the H7N9 and H1N1 groups. The procalcitonin (PCT) level, elevated lactic acid, and D-dimer rates on admission and PCT >0.5 ng/mL rate after onset were significantly higher in the H7N9 group than in the H1N1 group (P < .05). The severity of ARDS was more serious in the H7N9 group than in the H1N1 group (P < .05). The typical chest CT characteristics of the 2 groups were similar. A nodular shadow was extremely rare, and bronchiectasis was not observed. The pleural effusion rate was higher in the H7N9 group than in the H1N1 group (P < .05).

Treatment and prognosis

All patients were treated with antiviral drugs and other treatment measures (Table 3). The rate of invasive mechanical ventilation was significantly higher in the H7N9 group than in the H1N1 group (P < .05). The H7N9 group had longer durations of viral shedding from the onset of illness and from the initiation of antiviral therapy to a negative viral test result (P < .05) than the H1N1 group.
Table 3

Treatment and prognosis of the H7N9 and H1N1 groups.

Treatment and prognosis of the H7N9 and H1N1 groups. Over the course of the viral infections, the 2 groups presented with a variety of serious accompanying complications, of which the occurrence rates of alimentary tract hemorrhage, pneumothorax or septum emphysema, hospital-acquired pneumonia (HAP) and multiple organ dysfunction syndrome (MODS) were significantly higher in the H7N9 group than in the H1N1 group (P < .05). The hospital mortality rate of the H7N9 group was significantly higher than that of the H1N1 group (P < .05). During follow-up, residual lesions on chest CT could be observed in both groups. At the 6th month of follow-up, the rates of bronchiectasia, reticular opacities, fibrous stripes, and patchy opacities in the H7N9 group were significantly higher than those in the H1N1 group (P < .05). Most residual lesions were adjacent to the pleura and obvious pulmonary fibrosis changes with collapsed lung could be detected in some survivors in the H7N9 group.

Different subtypes of influenza viral infection correlate with the presence of severe ARDS and death

After the adjustments for baseline variables (age, sex, and coexisting diabetes), H7N9 influenza viral infection was associated with a higher risk of the presence of severe ARDS than H1N1 influenza viral infection (odds ratio [OR] 8.29, 95% confidence interval [CI] 1.53–44.94; P < .05; Table 4). The differences remained significant when the corrections for only age and sex were made and when no corrections for baseline variables were made (OR 10.20, 95% CI 1.97–52.40; P < .05 and OR 4.50, 95% CI 1.24–16.28; P < .05, respectively; Table 4).
Table 4

The association between the different subtypes of influenza viral infection and the risk of the presentation of severe ARDS and death.

The association between the different subtypes of influenza viral infection and the risk of the presentation of severe ARDS and death. After the adjustments for baseline variables (age, sex, and coexisting diabetes), the risk of death between the 2 subtypes of influenza viral infection (H7N9 and H1N1) was not significantly different (OR 5.09, 95% CI 0.67–38.65; P > .05; Table 4), though the differences were significant when corrections for only age and sex were made and when no corrections for baseline variables were made (OR 8.06, 95% CI 1.21–53.92; P < .05; OR 7.64, 95% CI 1.36–42.90; P < .05; Table 4).

Discussion

In our study, the proportions of underlying diseases in the patients with H7N9 and those with H1N1 complicated by ARDS were high at 50.0% and 42.3%, respectively, which indicated that the combination of underlying diseases had a significant effect on the severities of H7N9 and H1N1.[ Interestingly, 3 cases (16.7%) with coexisting schizophrenia were found in the H7N9 group. To our knowledge, there was no specific association between schizophrenia and the presence of H7N9 influenza viral infection, and the coexistence of the 2 diseases was considered coincidental. The presentation of ARDS in both the H7N9 and H1N1 patients was rapid after viral infection, along with a series of clinical symptoms. Notably, large amounts of bloody sputum production showing diffuse alveolar hemorrhage were more common among the H7N9 patients, which indicated that the viral injury to the H7N9 patients was more severe.[ In addition, H7N9 patients had similar patterns of leukopenia, lymphopenia, and thrombocytopenia and similar levels of creatine kinase, lactic dehydrogenase, alanine aminotransferase, and aspartic transaminase to those observed in the H1N1 patients. These experimental indexes were considered to be closely related to the severities of the H7N9 and H1N1 infections.[ The main manifestations on chest CT for both diseases were characterized by consolidations, ground-glass opacities (GGOs), and air bronchograms. Pleural effusion, interlobular septal thickening, and mediastinal or hilar lymphadenectasis were the second most common imaging abnormalities. The pleural effusion rate in the H7N9 group reached 88.9%, while the pleural effusion rate in the H1N1 group was only 7.7%, suggesting that the combination with pleural effusion might have a certain value in the differential diagnosis of the 2 diseases. During the follow-up period of the survivors, chest CT showed that the resolution of the lesions among the H7N9 patients was slow, which was consistent with the previously reported rate in the literature[ and which was similar to the rate among the patients with avian influenza A (H5N1) viral infection.[ In addition, pulmonary fibrosis changes were much more commonly observed in the H7N9 survivors. The main cause might have been the obviously prolonged viral shedding time during the H7N9 infection, which may have produced more severe damage to the lung tissue.[ More observations are needed to clarify further imaging changes in such patients. Notably, H7N9 influenza viral infection was associated with a significantly higher risk of the presence of severe ARDS. Specifically, as observed in our study, ARDS in the H1N1 group was mainly light and moderate, while ARDS in the H7N9 group was mainly severe, suggesting the relatively moderate conditions of the H1N1 patients.[ Since ARDS in the H7N9 group was much more severe, the necessity for mechanical ventilation was much higher, but the treatments for mild and moderate ARDS of the 2 groups were mainly based on noninvasive positive pressure ventilation (NPPV). A multiple-center survey[ indicated that when NPPV was applied as the first-line intervention for ARDS, intubation was avoided for 54% of treated patients, with less ventilator-associated pneumonia and a lower intensive care unit mortality rate. In addition, the multicenter trial reported by Zhan et al[ showed that the early application of NPPV for mild ARDS improved PaO2/FiO2 with time and decreased the proportion of patients requiring intubation with a lower number of organ failures and a trend towards reducing inhospital mortality. In our research, most of the patients with mild and moderate ARDS and some with severe ARDS in both groups were treated with NPPV and ultimately cured, indicating that the use of NPPV for mild and moderate ARDS had a good curative effect. However, additional prospective and comparative trials that address the need for intubation and the mortality rate as the outcomes of interest for patients with viral pneumonia and ARDS are required.

Conclusions

The patients with H7N9 complicated by ARDS had much more severe diseases with worse outcomes than the patients with H1N1. More changes in pulmonary were observed in the patients with H7N9 at the convalescent stage, and thus, these patients should be carefully followed up to further clarify their outcomes. Additional studies are needed to further the understanding of ARDS in patients with influenza.

Author contributions

Conceptualization: J. Huang. Data curation: C. Lan, H. Zhang, X. Wang, J. Pan. Formal analysis: H. Zhang, L. Chen, J. Huang. Methodology: H. Weng. Project administration: H. Li. Writing – original draft: H. Li, C. Lan, J. Huang. Writing – review & editing: H. Weng, J. Huang.
  16 in total

1.  Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico.

Authors:  Rogelio Perez-Padilla; Daniela de la Rosa-Zamboni; Samuel Ponce de Leon; Mauricio Hernandez; Francisco Quiñones-Falconi; Edgar Bautista; Alejandra Ramirez-Venegas; Jorge Rojas-Serrano; Christopher E Ormsby; Ariel Corrales; Anjarath Higuera; Edgar Mondragon; Jose Angel Cordova-Villalobos
Journal:  N Engl J Med       Date:  2009-06-29       Impact factor: 91.245

2.  Radiological features of lung changes caused by avian influenza subtype A H5N1 virus: report of two severe adult cases with regular follow-up.

Authors:  Pu-xuan Lu; Yi-xiang Wang; Bo-ping Zhou; Yang Ge; Wen-ke Zhu; Xin-chun Chen; Xian-gui Ran
Journal:  Chin Med J (Engl)       Date:  2010-01-05       Impact factor: 2.628

Review 3.  [ARDS and influenza A (H1N1): patients' characteristics and management in intensive care unit. A literature review].

Authors:  S Jaber; M Conseil; Y Coisel; B Jung; G Chanques
Journal:  Ann Fr Anesth Reanim       Date:  2010-02-08

4.  A multiple-center survey on the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome.

Authors:  Massimo Antonelli; Giorgio Conti; Antonio Esquinas; Luca Montini; Salvatore Maurizio Maggiore; Giuseppe Bello; Monica Rocco; Riccardo Maviglia; Mariano Alberto Pennisi; Gumersindo Gonzalez-Diaz; Gianfranco Umberto Meduri
Journal:  Crit Care Med       Date:  2007-01       Impact factor: 7.598

5.  Clinical findings in 111 cases of influenza A (H7N9) virus infection.

Authors:  Hai-Nv Gao; Hong-Zhou Lu; Bin Cao; Bin Du; Hong Shang; Jian-He Gan; Shui-Hua Lu; Yi-Da Yang; Qiang Fang; Yin-Zhong Shen; Xiu-Ming Xi; Qin Gu; Xian-Mei Zhou; Hong-Ping Qu; Zheng Yan; Fang-Ming Li; Wei Zhao; Zhan-Cheng Gao; Guang-Fa Wang; Ling-Xiang Ruan; Wei-Hong Wang; Jun Ye; Hui-Fang Cao; Xing-Wang Li; Wen-Hong Zhang; Xu-Chen Fang; Jian He; Wei-Feng Liang; Juan Xie; Mei Zeng; Xian-Zheng Wu; Jun Li; Qi Xia; Zhao-Chen Jin; Qi Chen; Chao Tang; Zhi-Yong Zhang; Bao-Min Hou; Zhi-Xian Feng; Ji-Fang Sheng; Nan-Shan Zhong; Lan-Juan Li
Journal:  N Engl J Med       Date:  2013-05-22       Impact factor: 91.245

6.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

7.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

8.  Critical care services and the H1N1 (2009) influenza epidemic in Australia and New Zealand in 2010: the impact of the second winter epidemic.

Authors:  Steven A R Webb; Cecile Aubron; Michael Bailey; Rinaldo Bellomo; Belinda Howe; Colin McArthur; Siouxzy Morrison; Ian Seppelt
Journal:  Crit Care       Date:  2011-06-09       Impact factor: 9.097

9.  Clinical features of the 2009 swine-origin influenza A (H1N1) outbreak in Japan.

Authors:  Koji Takayama; Jin Kuramochi; Takeshi Oinuma; Hiromi Kaneko; Satoshi Kurasawa; Makito Yasui; Kaori Okayasu; Hiroshi Ono; Naohiko Inase
Journal:  J Infect Chemother       Date:  2010-12-21       Impact factor: 2.211

10.  Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care.

Authors:  Jiajia Wang; Hua Xu; Xinjing Yang; Daguo Zhao; Shenglan Liu; Xue Sun; Jian-An Huang; Qiang Guo
Journal:  Braz J Infect Dis       Date:  2016-11-29       Impact factor: 3.257

View more
  11 in total

1.  H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets.

Authors:  Jørgen de Jonge; Harry van Dijken; Femke de Heij; Sanne Spijkers; Justin Mouthaan; Rineke de Jong; Paul Roholl; Eduardo Alfredo Adami; Milena Apetito Akamatsu; Paulo Lee Ho; Livia Brunner; Nicolas Collin; Martin Friede; José A Ferreira; Willem Luytjes
Journal:  NPJ Vaccines       Date:  2020-05-11       Impact factor: 7.344

2.  Comparison of acute respiratory distress syndrome in patients with COVID-19 and influenza A (H7N9) virus infection.

Authors:  Ling Ding; Yikun Chen; Nan Su; Xizhen Xu; Jingping Yin; Jun Qiu; Jiajia Wang; Dong Zheng
Journal:  Int J Infect Dis       Date:  2022-07-03       Impact factor: 12.074

3.  Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection.

Authors:  Harshini K Ashar; Sivasami Pulavendran; Jennifer M Rudd; Prasanthi Maram; Mallika Achanta; Vincent T K Chow; Jerry R Malayer; Timothy A Snider; Narasaraju Teluguakula
Journal:  Am J Pathol       Date:  2021-01-14       Impact factor: 4.307

4.  Comparison of the computed tomography findings in COVID-19 and other viral pneumonia in immunocompetent adults: a systematic review and meta-analysis.

Authors:  Stephan Altmayer; Matheus Zanon; Gabriel Sartori Pacini; Guilherme Watte; Marcelo Cardoso Barros; Tan-Lucien Mohammed; Nupur Verma; Edson Marchiori; Bruno Hochhegger
Journal:  Eur Radiol       Date:  2020-06-27       Impact factor: 5.315

5.  Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia.

Authors:  Fengxiang Song; Nannan Shi; Fei Shan; Zhiyong Zhang; Jie Shen; Hongzhou Lu; Yun Ling; Yebin Jiang; Yuxin Shi
Journal:  Radiology       Date:  2020-02-06       Impact factor: 11.105

6.  Long-term clinical prognosis of human infections with avian influenza A(H7N9) viruses in China after hospitalization.

Authors:  Qianli Wang; Hui Jiang; Yun Xie; Tianchen Zhang; Shelan Liu; Shenggen Wu; Qianlai Sun; Shaoxia Song; Wei Wang; Xiaowei Deng; Lingshuang Ren; Tiantian Qin; Peter Horby; Timothy Uyeki; Hongjie Yu
Journal:  EClinicalMedicine       Date:  2020-02-19

7.  A Hospital-Based Nonconcurrent Cohort Study on Factors Associated with in-Hospital Mortality in Patients with Laboratory Confirmed Influenza.

Authors:  Vijay Alexander; G Jackwin Sam Paul; Anand Zachariah; Alice Joan Mathuram
Journal:  J Glob Infect Dis       Date:  2020-11-30

8.  Comparative study of hematological and radiological feature of severe/critically ill patients with COVID-19, influenza A H7N9, and H1N1 pneumonia.

Authors:  Jindan Kong; Yan Hao; Shan Wan; Zheng Li; Di Zou; Leisi Zhang; Yin Lu; Jun Wang; Xiaochen Chen; Jianhong Fu
Journal:  J Clin Lab Anal       Date:  2021-11-11       Impact factor: 2.352

9.  H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets.

Authors:  Jørgen de Jonge; Harry van Dijken; Femke de Heij; Sanne Spijkers; Justin Mouthaan; Rineke de Jong; Paul Roholl; Eduardo Alfredo Adami; Milena Apetito Akamatsu; Paulo Lee Ho; Livia Brunner; Nicolas Collin; Martin Friede; José A Ferreira; Willem Luytjes
Journal:  NPJ Vaccines       Date:  2020-05-11       Impact factor: 7.344

10.  Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis.

Authors:  Laura Fabbri; Samuel Moss; Fasihul A Khan; Wenjie Chi; Jun Xia; Karen Robinson; Alan Robert Smyth; Gisli Jenkins; Iain Stewart
Journal:  Thorax       Date:  2022-03-25       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.